clinical trial · NCT06667141
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Specific Advanced Solid TumorsACR-2316
brief summary
This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
started
Oct 8, 2024
primary completion
Aug 12, 2026
completion
Dec 12, 2026
last updated
Mar 23, 2026
detailed description
The Phase 1 monotherapy clinical trial for ACR-2316 is designed to assess the safety and tolerability of ACR-2316. Additional objectives include the determination of the maximal tolerated dose and recommended Phase 2 monotherapy dose, characterization of the pharmacokinetic profile and pharmacogenomics, and preliminary evaluation of anti-tumor activity.
official title
ACR-2316-101: Phase 1 Study of ACR-2316 in Subjects With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol